BWXT Q3 deep dive: nuclear growth pipeline advances despite revenue miss

Aerospace and defense company BWX (NYSE:BWXT) fell short of the market’s revenue expectations in Q3 2026, but sales rose 10% year on year to $953 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.8 billion at the midpoint. Its non-GAAP profit of $1.26 per share was 5.7% above analysts’ consensus estimates.

Is now the time to buy BWXT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

BWX’s third quarter results were marked by a revenue increase of 10% year over year, but the outcome fell short of Wall Street’s expectations, prompting a negative market reaction. Management attributed the growth to strong execution in both government and commercial segments, continued operational efficiency, and a robust demand environment for nuclear solutions. CEO Rex Geveden emphasized expansion in advanced nuclear projects and the company’s ability to convert market demand into executable programs. The company highlighted increased manufacturing capacity and progress in special materials as key factors driving the quarter’s performance.

Looking ahead, BWX’s guidance is shaped by ongoing investments in manufacturing capacity and advanced fuel capabilities, with management focused on sustaining productivity improvements and scaling special material programs. The company anticipates high single-digit to low double-digit growth in adjusted EBITDA and earnings per share for next year, supported by core business expansion and new awards. CFO Mike Fitzgerald noted that free cash flow is expected to remain stable despite increased working capital to support growth. CEO Rex Geveden reiterated BWX’s confidence in achieving its long-term financial targets, stating, “Our performance this quarter underscores our confidence in the 2030 financial targets we established at Investor Day.”

Key insights from management’s remarks

Management cited strong growth in both core and newer programs, particularly in advanced nuclear and special materials, as well as enhanced operational efficiency and recent acquisition integration.

• Advanced nuclear project momentum: The company completed the core barrel assembly for Project Pele and secured new international and military contracts for its microreactor technology, including the U.S. Army’s Janus program and Prodigy Clean Energy in Canada.
• Special materials ramp-up: Defense fuels enrichment and high-purity depleted uranium (HPDU) programs accelerated, with construction underway on a new facility in Jonesborough, Tennessee, expected to drive revenue growth through 2027.
• Operational efficiency gains: Government operations benefited from improved efficiency in naval nuclear contracts and technical services, leading to higher adjusted EBITDA margins.
• Acquisition integration progress: The PCG acquisition contributed to commercial revenue growth, with management reporting better-than-expected cost synergies and underutilized capacity available for further expansion.
• Commercial power and international demand: The expansion of the Cambridge manufacturing facility increased heavy component capacity by 50%, supporting a growing backlog in Canadian and U.S. commercial nuclear projects. Management noted high interest in nuclear power from European markets, especially Poland.

Drivers of future performance

BWX’s outlook is anchored by sustained core business performance, growth in special materials and advanced nuclear, and productivity improvements.

• Scaling special materials and advanced nuclear: Management expects high single-digit to low double-digit growth in government operations, driven by continued ramp-up in defense fuel enrichment and HPDU programs, as well as increased activity in advanced nuclear projects.
• Commercial segment transitions: Organic revenue growth in commercial operations is projected to remain robust, supported by component manufacturing and services, though tempered by the planned divestiture of the higher-margin medical business. Adjusted EBITDA margins are anticipated to improve due to operational efficiencies and better absorption of growth investments.
• Investment and cash flow discipline: Free cash flow is expected to be flat to slightly higher year on year, as increased working capital and capital expenditures are balanced by earnings growth. Management highlighted ongoing capital allocation toward organic growth, with share repurchases used mainly to offset dilution. Risks include timing of commercial order flow and execution of new program ramps.

Catalysts in upcoming quarters

Moving forward, the StockStory team will watch (1) the pace and scale of new commercial nuclear orders, especially for microreactors and large component contracts; (2) the ramp-up and execution of special materials and HPDU programs; and (3) margin trends in commercial operations as the medical business divests and manufacturing expansions come online. Progress on international opportunities and timely order conversion will also be important indicators of future growth.

BWX currently trades at $127.75, down from $130.47 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.